The Mid-Cap Japanese Pharmaceutical Sector: Evolving to Survive in the Face of Rising Competition

Introduction

As in-licensing opportunities are reduced and competition for market share in Japan increases with the rising penetration of western pharma companies, domestic mid-cap players must alter their strategies to remain independent. How can the evolution of the mid-cap Japanese sector be exploited to maximize competitive edge? This analysis provides you with the insight needed to understand the changing dynamics within the Japanese market and the evolving role of the mid-cap players to 2007.

Scope

Benchmarking of the leading players in the Japanese market by 2001 sales, operating profits and R&D spend and by forecast sales between 2002 and 2007 

In-depth analysis of product sourcing and geographic expansion strategies of mid-cap Japanese companies and assessment of the winners and losers 

Profiles of 8 leading mid-cap companies: Dainippon, Japan Tobacco, Kirin Brewery, Kyorin, Kyowa Hakko Kogyo, Ono Pharmaceutical, Sumitomo and Tanabe 

1,3 and 6 year forecasts for key products, therapeutic franchises and total ethical sales for the 8 profiled companies 

Drug forecasts benchmarked against analyst consensus estimates from leading investment houses 

Report Highlights

Geographic expansion will be a key driver for growth in the mid-cap sector, and those companies successful in establishing joint ventures with western partners will the be most likely to maximize revenues. 

Companies that rely heavily on in-licensing and co-development are likely to find it increasingly hard to source products, while those with strong internal R&D may find themselves the target of aggressive M&A activity. However, R&D expenditure as a proportion of total sales is lower for Japanese companies than for western pharmaceutical ones, at 11.9 pe cent compared to 13.8 percent. 

Reasons to Purchase

Assess the impact of rising western company penetration of the Japanese market on the dynamics of the mid-cap players 

Understand the drivers of growth of the major mid-cap players and evaluate the opportunities these may present  

Realize the benefits and limitations of alliance networks with mid-cap Japanese players 

Effectively implement product sourcing strategies to maximize profit return 

Benchmark your strategy against key rivals in the mid-cap Japanese sector 

Publisher: Datamonitor Market and Sales Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Market_and_Sales.html#a293